POS1264 LONGITUDINAL FOLLOW-UP OF HUMORAL RESPONSE AGAINST SARS-CoV-2 AND VIRAL PERSISTENCE IN 96 DMARDs-TREATED PATIENTS WITH PREVIOUS COVID-19 INFECTION

Background Although it prevents severe forms of the disease, vaccination does not completely protect against occurrence COVID19 disease. If, DMARDs used have been associated with variable humoral response to SARS-CoV-2 vaccination, impact their use after natural infection poorly studied. Objectives To characterize and viral persistence in nasopharyngeal sphere (NP), stools blood patients rheumatic disease under DMARDs, compared healthy controls. Methods Prospective monocentric longitudinal study including rheumatoid arthritis or spondyloarthritis a confirmed (positive NP PCR and/or positive serology pathognomonic thoracic tomography (CT)) during first second wave COVID pandemic. Patients were followed up until one year was assessed before vaccination. Serum IgG IgA antibodies spike (S) nucleocapsid (N) proteins measured at every visit. Viral early visit using conventional RT-PCR high sensitive technique (droplet digital PCR). Results Between June 2020 July 2021, we include 96 (50 SpA 46 RA) mean age 53 +/- 14 years 20 controls (mean 49 ± 16 years) corresponding relatives (spouses, children) living together infected same time. The immune responses analyzed according 6 treatment groups: methotrexate (MTX)/salazopyrine (SLZ) monotherapy (n=17/2); anti-TNF (n=24), + MTX (n=23); rituximab (RTX) (n=11); anti-IL17 -23 (n=8); others (n=11). Visits made 1 month (29 ±13 days; n=18), 3 months (110 ±23 n=67), (231 ±35 n=48) 12 (368 19 n=19) infection. anti-S anti-N Ab titers significantly different groups control population months. A significant decrease noted group treated RTX (p=0.007) molecules targeting IL17/23 pathway (p=0.007). similar but non-significant trend observed these for (p=0.07). anti-SARS-CoV-2 M3, Detection SARS-Cov-2 RNA serum negative all samples taken 4 (2 RA abatacept/RTX 2 anti-TNF/secukinumab) had low very load 1-month Ct 36). None form Conclusion - previous proven COVID-19 did seem alter anti-IL17/-IL-23 might response. This lower more In patients, new may be considered as full boost system. induce serum, stool. Acknowledgements financial support from Société Française de Rhumatologie ANR Disclosure Interests declared